• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay

tetano

Editor, Senior Moderator
PLoS One


. 2022 Jul 28;17(7):e0272298.
doi: 10.1371/journal.pone.0272298. eCollection 2022.
Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay


Anders Frische[SUP] 1 [/SUP], Patrick Terrence Brooks[SUP] 2 [/SUP], Mikkel Gybel-Brask[SUP] 2 [/SUP], Susanne Gjørup Sækmose[SUP] 3 [/SUP], Bitten Aagaard Jensen[SUP] 4 [/SUP], Susan Mikkelsen[SUP] 5 [/SUP], Mie Topholm Bruun[SUP] 6 [/SUP], Lasse Boding[SUP] 7 [/SUP], Charlotta Polacek Strandh[SUP] 1 [/SUP], Charlotte Sværke Jørgensen[SUP] 1 [/SUP], Karen Angeliki Krogfelt[SUP] 1 8 [/SUP], Anders Fomsgaard[SUP] 1 9 [/SUP], Ria Lassauniere[SUP] 1 [/SUP]



Affiliations

Abstract

Virus neutralization assays provide a means to quantitate functional antibody responses that block virus infection. These assays are instrumental in defining vaccine and therapeutic antibody potency, immune evasion by viral variants, and post-infection immunity. Here we describe the development, optimization and evaluation of a live virus microneutralization assay specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this assay, SARS-CoV-2 clinical isolates are pre-incubated with serial diluted antibody and added to Vero E6 cells. Replicating virus is quantitated by enzyme-linked immunosorbent assay (ELISA) targeting the SARS-CoV-2 nucleocapsid protein and the standardized 50% virus inhibition titer calculated. We evaluated critical test parameters that include virus titration, assay linearity, number of cells, viral dose, incubation period post-inoculation, and normalization methods. Virus titration at 96 hours was determined optimal to account for different growth kinetics of clinical isolates. Nucleocapsid protein levels directly correlated with virus inoculum, with the strongest correlation at 24 hours post-inoculation. Variance was minimized by infecting a cell monolayer, rather than a cell suspension. Neutralization titers modestly decreased with increasing numbers of Vero E6 cells and virus amount. Application of two different normalization models effectively reduced the intermediate precision coefficient of variance to <16.5%. The SARS-CoV-2 microneutralization assay described and evaluated here is based on the influenza virus microneutralization assay described by WHO, and are proposed as a standard assay for comparing neutralization investigations.
 
Back
Top Bottom